1. Introduction {#sec1}
===============

Diabetic retinopathy (DR) is one of the most common microvascular complications of diabetes mellitus (DM) and a leading cause of adult blindness worldwide \[[@B1], [@B2]\]. Although long duration of diabetes and poor control of glycemia have been considered as the major risk factors for the development of DR, accumulated evidences suggest a genetic influence on susceptibility to this complication \[[@B3]\]. A number of genes have been suggested as candidate genes of diabetic retinopathy, for example, methylenetetrahydrofolate reductase gene, endothelial nitric oxide synthase gene (eNOS), vascular endothelial growth factor gene, and so on \[[@B4]--[@B6]\].

The eNOS gene is located on chromosome 7q35-36 and includes 26 exons, spanning 21 kb. The polymorphism of eNOS 4b/a gene consists of the two alleles of eNOS 4a with 4 tandem 27-repeats and eNOS 4b with 5 repeats \[[@B7]\]. NO is produced through the oxidation of L-arginine by eNOS \[[@B8]\]. NO can regulate endothelial function and is an important factor in the maintenance of homeostasis. NO can contribute to vasodilatation, increase local blood flow, and decrease vascular resistance in ocular circulation. Studies on humans and animal models have suggested that eNOS plays an essential role in retinal vascular function and disequilibrium in its production can lead to the development of DR \[[@B9]--[@B11]\]. The presence of eNOS polymorphisms might contribute to a decreased eNOS activity and a reduced NO level and has been reported to be a potential factor in the pathogenesis and development of DR.

To date, many case-control studies have been carried out to investigate the relationship between eNOS-4b/a polymorphism and the risk of DR among type 2 diabetic subjects, but results of these studies were conflicting and inconclusive. Some studies observed that there was an association between eNOS-4b/a polymorphism and the risk of DR \[[@B4], [@B12]\], while some others suggested there was no significant association \[[@B13], [@B14]\]. To draw a more reliable conclusion, we performed a meta-analysis of all available studies dealing with the relationship between the eNOS-4b/a polymorphism and DR among type 2 diabetic subjects, including subgroup analyses based on different ethnicities.

2. Materials and Methods {#sec2}
========================

2.1. Literature Search Strategy {#sec2.1}
-------------------------------

We searched the literature databases including Pubmed, Embase, China National Knowledge Infrastructure (CNKI), and Chinese Wanfang Database. The last updated search was performed on November 20, 2013. The search used the following terms: "endothelial nitric oxide synthase or eNOS or 4b/a" in combination with "mutation or polymorphism or variant" and in combination with "diabetic retinopathy or DR." We also manually searched all the references of included studies to further identify additional relevant studies. Unpublished studies were not sought. For overlapping or republished studies, only the larger sample size or the most recent published papers were included in this meta-analysis. Publication language and publication date were not restricted in our search.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Studies included in this meta-analysis must meet the following criteria: (1) case-control or cohort studies; (2) studies evaluating the association between eNOS-4b/a polymorphism and DR risk; (3) subjects in the control group having type 2 diabetes but being free of DR; (4) human studies; and (5) having detailed data to calculate the odds ratio (OR) and 95% confidence interval (CI).

Studies were excluded if one of the following existed: (1) review articles or editorials; (2) case reports; (3) repeating or overlapping publications; (4) no report about the genotype frequency or insufficient information for data extraction.

2.3. Data Extraction {#sec2.3}
--------------------

The following data were collected from each study: first author, publication date, region, ethnicity, sample size of cases and controls, genotype and allele frequencies of cases and controls, and genotyping methods. All the data were extracted independently by two investigators (Ze-jun Ma and Hui-Zhu Ren), according to the inclusion criteria above. Disagreements about eligibility were resolved through a discussion between the two investigators.

2.4. Statistical Analysis {#sec2.4}
-------------------------

In this meta-analysis, we evaluated the relationship between eNOS-4b/a polymorphism and DR risk using the allelic model (a versus b), the additive model (aa versus bb), the dominant model (aa + ab versus bb), and the recessive model (aa versus ab + bb) (see [Figure 5](#fig5){ref-type="fig"}). The alleles and genotypes between patients and control subjects were compared with OR and corresponding 95% CIs. A chi-square based*Q* statistics test and*I* ^2^ test were used to evaluate the heterogeneity between the studies (*P* \< 0.10 and*I* ^2^ \> 50% indicated the evidence of heterogeneity) \[[@B15]\]. The fixed effects model (FEM) was used when there was no statistical heterogeneity among the included studies; otherwise, the random effects model (REM) was used. Subgroup analysis was conducted according to different ethnicity. Sensitivity analysis was performed for estimating the stability of the meta-analysis. First, sensitivity analysis was carried out by exclusion of studies which failed the HWE test. Another analysis was done by omitting one study at a time to examine influence of one study on the overall summary estimate. Begg\'s funnel plot and Egger\'s test were carried out to assess possible publication bias \[[@B16], [@B17]\]. Asymmetric plot or the *P* value of Egger\'s test less than 0.05 suggested possible publication bias. Meta-analyses were performed using the statistical software Review Manager (version 5.2 for Windows, Cochrane Collaboration) and STATA software (version 12.0; Stata, College Station, TX), using two-sided *P* values.

3. Results {#sec3}
==========

3.1. Characteristics of the Studies {#sec3.1}
-----------------------------------

Based on our search strategy, 61 potentially relevant articles were identified in Pubmed, Embase, CNKI, and Chinese Wanfang Database. A flow chart of study selection was shown in [Figure 1](#fig1){ref-type="fig"}. Of these, 46 were excluded because they did not meet the criteria or were overlapping publications. Finally, a total of 15 studies published between 2004 and 2012 met our inclusion criteria, involving 3,183 cases and 3,410 controls. The main characteristics of these studies were listed in [Table 1](#tab1){ref-type="table"}. Of the ethnicity among all studies, four studies were performed on Caucasians \[[@B4], [@B13], [@B14], [@B18]\], ten were performed on Asian \[[@B12], [@B19]--[@B27]\], and one study was performed on West African \[[@B28]\]. The sample size in these studies varied considerably (ranging from 166 to 1446 individuals). The genotype and allele distributions for each study and HWE in controls were summarized in [Table 2](#tab2){ref-type="table"}. Two genotyping methods were used to check genotypes in the studies including polymerase chain reaction (PCR) or PCR-restriction fragment length polymorphism (PCR-RFLP).

The distribution of the eNOS 4b/a genotype in control group was consistent with the HWE, except for two studies \[[@B23], [@B26]\]. Because excluding these two studies did not materially affect the results, they were still included in this analysis.

3.2. Meta-Analysis Results {#sec3.2}
--------------------------

The main results of meta-analysis for eNOS 4b/a polymorphism with the risk of DR were shown in [Table 3](#tab3){ref-type="table"}. No significant association between eNOS 4b/a polymorphism and susceptibility to DR was identified in any of the genetic models (allelic model: OR = 0.94, 95% CI: 0.79--1.11; additive model: OR = 0.91, 95% CI: 0.73--1.14; the recessive model: OR = 1.01, 95% CI: 0.81--1.25; and the dominant model: OR = 0.91, 95% CI: 0.75--1.09) (Figures [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and [4](#fig4){ref-type="fig"}).

In the subgroup analysis by ethnicity, similarly, there was still no significant association detected in all genetic models among Asians and Caucasians. The results of the subgroup analyses were shown in [Table 3](#tab3){ref-type="table"}.

3.3. Heterogeneity and Publication Bias {#sec3.3}
---------------------------------------

Some heterogeneity was found during the course of the study. Hence, the random effects model was used. Begg\'s funnel plot and Egger\'s test were performed to assess the publication bias of the eligible literatures in this meta-analysis. The shapes of the funnel plots in all genetic models did not reveal any evidence of obvious asymmetry. The Egger\'s test further confirmed the absence of publication bias for any of the four genetic models in this meta-analysis (*P* = 0.277 for dominant model, *P* = 0.313 for recessive model, *P* = 0.287 for additive model, and *P* = 0.764 for allelic model, resp.).

3.4. Sensitivity Analysis {#sec3.4}
-------------------------

Sensitivity analyses were performed to assess the stability of the results. Although two studies \[[@B23], [@B26]\] did not follow the HWE, the summary ORs were not materially altered including or excluding the studies (data shown in [Table 3](#tab3){ref-type="table"}). Moreover, no other single study influenced the overall results (data not shown), which indicated that our results were statistically reliable and robust.

4. Discussion {#sec4}
=============

The polymorphism of eNOS-4b/a gene has been associated with many vascular diseases including hypertension, diabetic retinopathy, and diabetic nephropathy in various populations \[[@B29], [@B30]\]. Variable results have been reported for the association of eNOS-4b/a polymorphism with DR \[[@B13], [@B20], [@B21]\]. In a systematic meta-analysis study \[[@B3]\], no relationship of the eNOS 4b/a polymorphism was found with DR development regardless of ethnicity. However, a recent meta-analysis study found that eNOS 4b/a has a protective effect against DR \[[@B31]\]. The present meta-analysis of 15 studies, including 3,183 cases and 3,410 controls, provided the most comprehensive analysis on the association of the eNOS 4b/a polymorphism with the risk of diabetic retinopathy. The results indicated that the eNOS 4b/a polymorphism was not associated with an increased risk of DR in the overall studied population. These findings were consistent with most of the studies that were included in our meta-analysis \[[@B13], [@B14], [@B23]\]. The lack of association between eNOS 4b/a polymorphism and diabetic retinopathy suggested that genetic variations in the eNOS 4b/a gene did not predict the risk of diabetic retinopathy in T2DM patients. It is possible that eNOS-derived NO plays a minor role in the development of diabetic retinopathy. In the subgroup analysis according to ethnicity, no significant association was observed in Asian and Caucasians in all genetic models. The results demonstrated that ethnic difference in genetic background and the living environment did not play an obvious role in the association between the eNOS 4b/a polymorphism and the risk of DR. Although the available genetic data do not implicate the eNOS 4b/a polymorphism as a determinant of DR susceptibility in Asian and Caucasians, further studies are needed to see if the eNOS 4b/a polymorphism can confer a risk of DR in other ethnic populations.

Publication bias is an important factor affecting us to get a reliable conclusion for meta-analysis. In this meta-analysis, no significant publication bias for 4b/a polymorphism in any of the above-mentioned inherited models was found, suggesting that the results observed should be stable. Sensitivity analyses did not significantly alter the results, also suggesting that our results were statistically reliable and stable.

Our study has several limitations that need to be taken into consideration when interpreting the results. First, significant between-study heterogeneity was detected in some comparisons and might distort the meta-analysis. Second, only published studies in English or Chinese were included for data analysis; some potential studies with other languages or unpublished could be missed. Third, this meta-analysis was based predominantly on Asian research. Only 4 studies involving Caucasians and one study involving Africans were included. No study from other parts of the world was found. This may develop a partial result. Fourth, our meta-analysis was based on unadjusted OR estimates. Despite these limitations, our study provides a better understanding of the association between eNOS-4b/a gene polymorphisms and risk of DR in type 2 diabetes.

In summary, this meta-analysis indicates that the eNOS 4b/a polymorphism is not associated with an increased risk of DR among type 2 diabetic subjects. Taking into account the limitations of this meta-analysis, further larger well-designed studies involving different ethnic populations, particularly referring to gene-gene and gene-environment interactions, are required to confirm this finding.
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###### 

Main characteristics of included studies in the meta-analysis.

  Author                              Year   Country             Ethnicity      Case/control   Genotyping methods
  ----------------------------------- ------ ------------------- -------------- -------------- --------------------
  Awata et al. \[[@B12]\]             2004   Japan               Asian          117/109        PCR
  Cheema et al. \[[@B20]\]            2012   Indian              Asian          842/604        PCR-RFLP
  Chen et al. \[[@B28]\]              2007   Ghana and Nigeria   West African   68/301         PCR
  Cilenšek et al. \[[@B4]\]           2012   Slovenia            Caucasians     172/405        PCR
  de Syllos et al. \[[@B14]\]         2006   Brazil              Caucasians     56/114         PCR
  Ezzidi et al. \[[@B19]\]            2008   Bahrain             Asian          383/489        PCR-RFLP
  Li et al. \[[@B26]\]                2010   china               Asian          87/79          PCR
  Mehrab-Mohseni et al. \[[@B21]\]    2011   Iran                Asian          41/179         PCR
  Petrovič et al. \[[@B18]\]          2008   Slovenia            Caucasians     283/143        PCR
  Santos et al. \[[@B13]\]            2012   Brazil              Caucasians     407/184        PCR
  Suganthalakshmi et al. \[[@B22]\]   2006   India               Asian          120/90         PCR-RFLP
  Sun et al. \[[@B24]\]               2004   china               Asian          147/155        PCR-RFLP
  Uthra et al. \[[@B23]\]             2007   India               Asian          187/188        PCR
  Yue et al. \[[@B27]\]               1994   china               Asian          154/167        PCR
                                                                                               
  Zhang et al. \[[@B25]\]             2005   china               Asian          119/203        PCR

###### 

The distribution of the 4b/a genotype and allele frequency for cases and controls.

  Study                               Distribution of 4b/a eNOS genotype   Allele frequency   HWE                                             
  ----------------------------------- ------------------------------------ ------------------ ----- ---- ----- ----- ----- ------ ----- ----- -----
  Awata et al. \[[@B12]\]             1                                    25                 91    3    24    82    27    207    30    188   Yes
  Cheema et al. \[[@B20]\]            87                                   344                411   66   270   268   518   1166   402   806   Yes
  Chen et al. \[[@B28]\]              10                                   17                 41    48   136   117   37    99     232   370   Yes
  Cilenšek et al. \[[@B4]\]           15                                   51                 106   13   114   278   81    263    140   670   Yes
  de Syllos et al. \[[@B14]\]         1                                    16                 39    3    27    84    18    94     33    195   Yes
  Ezzidi et al. \[[@B19]\]            17                                   115                251   33   180   276   149   617    246   732   Yes
  Li et al. \[[@B26]\]                5                                    13                 69    7    11    61    23    151    25    133   No
  Mehrab-Mohseni et al. \[[@B21]\]    12                                   111                284   5    53    126   135   679    63    305   Yes
  Petrovič et al. \[[@B18]\]          16                                   91                 176   7    44    92    123   443    58    228   Yes
  Santos et al. \[[@B13]\]            12                                   111                284   5    53    126   135   679    63    305   Yes
  Suganthalakshmi et al. \[[@B22]\]   7                                    27                 86    3    18    69    41    199    24    156   Yes
  Sun et al. \[[@B24]\]               3                                    36                 108   1    21    133   42    252    23    287   Yes
  Uthra et al. \[[@B23]\]             7                                    54                 126   1    57    130   68    306    59    317   No
  Yue et al. \[[@B27]\]               2                                    27                 125   4    45    118   31    277    53    281   Yes
  Zhang et al. \[[@B25]\]             0                                    11                 108   2    31    170   11    227    35    371   Yes

HWE: Hardy-Weinberg equilibrium, *P* \< 0.05 was considered significant.

###### 

Meta analysis of the association of eNOS-4b/a gene polymorphism with DR in type 2 diabetes.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Genetic model       Populations   Studies (*n*)   Number of cases/controls   Heterogeneity \      *I* ^2^ (%)               OR (95% CI)               *P* value
                                                                               *Q* test *P*-value                                                       
  ------------------- ------------- --------------- -------------------------- -------------------- ------------------------- ------------------------- -----------
  a versus b          All           15              3183/3410                  0.0005               64                        0.94 (0.79--1.11) (REM)   0.48

  Asian               10            2265/2564       0.006                      61                   0.90 (0.73--1.11) (REM)   0.32                      

  Caucasians          4             918/846         0.30                       18                   1.17 (0.97--1.40) (FEM)   0.10                      

  HWE (yes)           13            2909/3143       0.0003                     67                   0.93 (0.77--1.12) (REM)   0.44                      

                                                                                                                                                        

  aa versus bb        All           15              3183/3410                  0.04                 43                        0.91 (0.73--1.14) (FEM)   0.40

  Asian               10            2265/2564       0.21                       24                   0.78 (0.61--1.01) (FEM)   0.06                      

  Caucasians          4             918/846         0.26                       25                   1.64 (0.98--2.73) (FEM)   0.06                      

  HWE (yes)           13            2909/3143       0.06                       41                   0.88 (0.70--1.11) (FEM)   0.28                      

                                                                                                                                                        

  aa + ab versus bb   All           15              3183/3410                  0.002                60                        0.91 (0.75--1.09) (REM)   0.30

  Asian               10            2265/2564       0.0004                     61                   0.82 (0.65--1.04) (REM)   0.11                      

  Caucasians          4             918/846         0.58                       0                    1.13 (0.91--1.40) (FEM)   0.26                      

  HWE (yes)           13            2909/3143       0.0007                     65                   0.89 (0.72--1.10) (REM)   0.30                      

                                                                                                                                                        

  aa versus bb + ab   All           15              3183/3410                  0.21                 22                        1.01 (0.81--1.25) (FEM)   0.96

  Asian               10            2265/2564       0.49                       0                    0.90 (0.70--1.15) (FEM)   0.39                      

  Caucasians          4             918/846         0.28                       21                   1.60 (0.97--2.65) (FEM)   0.07                      

  HWE (yes)           13            2909/3143       0.30                       14                   0.98 (0.78--1.23) (FEM)   0.88                      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

OR: odds ratio; CI: confidence interval.

[^1]: Academic Editor: Nikolaos Papanas
